Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

1st Glaucoma Trial Completion

10 Jan 2006 09:18

Seeing Machines Limited10 January 2006 10 January 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES FIRST MAJOR CLINICAL TRIAL Seeing Machines Limited (AIM : SEE), a leading developer of advanced computerbased imaging software systems, announces the completion of the first majorclinical trial of its new groundbreaking technology for objective detection andmanagement of glaucoma, the group of eye diseases that affect peripheral vision,often leading to permanent loss of vision. Seeing Machines is developing a new medical device that assists clinicians todiagnose and manage disorders of the human visual system, particularly glaucoma. This recent trial has demonstrated with meaningful clinical utility, that thetechnology, as it stands today: • successfully detects the loss of visual field associated withglaucoma, and • successfully differentiates between those patients with visual fieldloss and those without, thus providing the basis for a reliable and accuratediagnostic instrument. Furthermore the trial has demonstrated significant opportunities for greatlyimproving the performance of the technology from the base-line used in thistrial. Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said: "The technical progress demonstrated in this trial has assisted Seeing Machinesin reaching a key milestone of our entire medical device development program.Our scientific teams, led by Drs. Ted Maddess and Andrew James from theAustralian National University, have done a tremendous job so far and we are nowwell advanced in the development work arising from this trial. The preparationsfor the next major clinical trial aimed at testing these developments are wellunderway with an anticipated start date this quarter. We are very excited aboutthese results and keen to build further on them as we pursue our goal ofdelivering the world's first non-contact objective test for glaucoma." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Jun 201912:53 pmRNSHolding(s) in Company
5th Jun 20191:03 pmRNSSenior Leadership Transition
16th May 20197:00 amRNSFleet Update
30th Apr 20192:58 pmRNSHolding(s) in Company
30th Apr 20197:00 amRNSDirectorate Change
25th Apr 201910:18 amRNSHolding(s) in Company
23rd Apr 20198:34 amRNSResult of GM, Offer and Total Voting Rights
10th Apr 20197:00 amRNSAutomotive deal with Joyson for US OEM
5th Apr 20197:00 amRNSSeeing Machines partners with Australian insurer
2nd Apr 201912:01 pmRNSIssue of Equity and Total Voting Rights
25th Mar 20192:00 pmRNSPosting of Offer Documents & Notice of GM
22nd Mar 20197:00 amRNSSubscription by Directors & Senior Management
20th Mar 201911:35 amRNSConditional Placing & Subscription to raise £27.5m
20th Mar 201911:29 amRNSHalf-year Report to 31 December 2018
8th Mar 20197:00 amRNSEye tracking technology trial with Toll
22nd Feb 20198:30 amRNSEU mandates safety technology for vehicles
19th Feb 20197:00 amRNSSixth Automotive OEM Design Win
16th Jan 20197:00 amRNSHalf year trading update
14th Jan 20197:00 amRNSCadillac Super Cruise 2019 Technology of the Year
13th Dec 20187:00 amRNSBoard Changes
12th Dec 20187:00 amRNSCollaboration with L3 to deliver eye tracking
6th Dec 20182:33 pmRNSIssue of Shares and Total Voting Rights
3rd Dec 20187:00 amRNSLuke Oxenham appointed Chief Financial Officer
26th Nov 20187:00 amRNSAviation division signs deal with Air Force
23rd Nov 20187:00 amRNSChief Financial Officer
16th Nov 20187:00 amRNSAppoints Paul McGlone to head Fleet division
14th Nov 20187:00 amRNSAGM Statement
14th Nov 20187:00 amRNSResult of AGM
22nd Oct 201810:27 amRNSNotice of AGM
17th Oct 20187:00 amRNSSeeing Machines appoints Ryan Murphy as COO
28th Sep 201811:05 amRNSIssue of Shares
19th Sep 20187:00 amRNSYear end results
11th Sep 20187:00 amRNSSeeing Machines launches Guardian BdMS
4th Sep 20182:06 pmRNSSecond Price Monitoring Extn
4th Sep 20182:00 pmRNSPrice Monitoring Extension
4th Sep 201811:05 amRNSSecond Price Monitoring Extn
4th Sep 201811:00 amRNSPrice Monitoring Extension
4th Sep 201810:19 amRNSSeeing Machines Limited Fleet Business Unit Update
29th Aug 20187:00 amRNSGuardian DMS covers more than 1 billion km
23rd Aug 201812:02 pmRNSTransfer of Ordinary Shares
16th Aug 201811:09 amRNSHolding(s) in Company
15th Aug 20189:41 amRNSIssue of Shares for Vested Performance Rights
9th Aug 20187:00 amRNSSeeing Machines leads pilot training collaboration
3rd Aug 20187:00 amRNSYear end trading update
27th Jul 20187:00 amRNSOEM Design Award
16th Jul 20187:00 amRNSBoard changes
5th Jul 20187:00 amRNSUS Fleet (Guardian) Contract
28th Jun 20181:27 pmRNSHolding(s) in Company
15th Jun 201810:43 amRNSKey Staff Recognised
7th Jun 201811:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.